Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
Lung cancer patients are at heightened risk for COVID-19 and the reported high mortality rate among lung cancer patients with COVID-19 has given pause to oncologists who are faced with patients with not one, but two severe, life-threatening diseases.
In what is believed to be a first-of-its-kind study to evaluate the safety of a type of immunotherapy before surgery in patients with an aggressive form of skin cancer, researchers report that the treatment eliminated pathologic evidence of cancer in nearly half of the study participants undergoing surgery.
Oncotarget Volume 11 Issue 16 showed that the sensitivity of H1299 and A549 cells to concomitant treatment with PAC and WFA was greater than that of either PAC or WFA alone.
Tejas Patil, MD, is a medical oncologist. Lisa Ferrigno, MD, MPH, FACS, is a trauma surgeon. Working with lung cancer patients at University of Colorado Cancer Center, they both, independently, noticed something strange:
Immunotherapy drugs that target a protein called programmed death ligand 1 (PD-L1) on the surface of cancer cells have quickly become a mainstay to treat many forms of cancer, often with dramatic results. But exactly how cancer cells turn on this protein was not completely understood.
The survival rates for patients with non-small cell lung cancer have improved greatly over the past decade thanks to several new targeted treatment options for patients.
The U.S. Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis.
Researchers from Zhongnan Hospital of Wuhan University in China in collaboration with those from the National Cancer Centre Singapore, have come up with a study that reveals the transmission of the SARS-CoV-2 or novel coronavirus among patients with cancer in China.
Lung cancer is the leading cause of cancer-associated deaths in the United States. Non-small cell lung cancer (NSCLC), a group of lung cancers named for the kinds of cells found in the cancer, constitutes more than 80% of all lung cancer cases.
Gero, the leader in AI-driven drug discovery, has used its AI platform to identify the potential anti-COVID-19 drugs. Six of them have been approved, three were withdrawn, and the other nine have been already tested in clinical trials for other indications.
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St. Michael's Hospital of Unity Health Toronto and Harvard Medical School.
Whether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to kill them, diverse mutations make cells resistant to chemicals, and "second generation" approaches are needed.
Artificial intelligence deep learning algorithms may predict response to systemic treatment for non-small cell lung cancer.
Oncotarget Volume 11, Issue 11 reported that at clinical progression, 64 EGFR T790M plasma positive patients were subjected to second line-treatment with osimertinib and strictly monitored during the first month of therapy.
Using standard-of-care computed tomography scans in patients with advanced non-small cell lung cancer, researchers utilized artificial intelligence to train algorithms to predict tumor sensitivity to three systemic cancer therapies.
Non-small cell lung cancer (NSCLC) is the most commonly diagnosed cancer, and the leading cause of cancer death worldwide.
The use of PET-CT imaging gives doctors the best possible picture of non-small cell lung cancer, and this accurate imaging helps to match patients with the best treatments.
Non-small cell lung cancer patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.
The Cancer Prevention and Research Institute of Texas has awarded new grants totaling $1.8 million to two University of Texas at Dallas scientists for their research related to lung and kidney cancers.
Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer.